Effect of recombinant human endostatin combined with chemotherapy on chemotherapy response and VEGF expression in patients with advanced malignant tumor
10.3969/j.issn.1005-1678.2017.05.012
- VernacularTitle:重组人血管内皮抑制素联合化疗对中晚期恶性肿瘤患者化疗效果及血管内皮生长因子水平的影响
- Author:
Qin ZHANG
;
Huafei CHEN
;
Youcai ZHU
- Keywords:
malignant tumor;
recombinant human endostatin;
chemotherapy;
angiogenic factor
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):41-43,46
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of recombinant human endostatin combined with chemotherapy on the expression of vascular endothelial growth factor (VEGF) in patients with advanced cancer.Methods250 patients with advanced malignant tumors were randomly selected from February 2012 to February 2016 the Third Hospital of Jiaxing, with unit control method experiment principle divided into two groups: experimental group (125 cases) and control group (125 cases).The experimental group treated by recombinant human endostatin combined chemotherapy, control group received routine chemotherapy for a week during the period of 21 days, after two cycles of treatment, clinical efficacy and adverse reactions of the two groups of patients were compared, and the expression of VEGF in tumor blood vessels weredetected.ResultsAfter two cycles of treatment, objective response rate, disease control rate in the experimental group patients was significantly higher than that in control group (P<0.05);after treatment, the expression level of VEGF in serum of the experimental group and the control groupwere decreased significantly, but the experimental group was lower than that of control group was more obvious (P<0.05).ConclusionRecombinant human endostatin combined with chemotherapy in the treatment of advanced malignant tumors can enhance the effect of chemotherapy, regulate the level of VEGF.
